• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Surescripts and GoodRx Partner to Advance Patient Price Transparency

    1/13/26 8:00:00 AM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email

    Surescripts Introduces New Patient Experience Solution to Transform the Medication Experience and Improve Patient Access, Affordability and Adherence

    Surescripts®, the nation's leading health intelligence network, introduces its Patient Experience product, Script Corner™, to transform the medication experience and empower patients by bringing together prescription benefit data, medication management and personalized engagement. Script Corner will include patient price transparency, including discounted cash prices through an exclusive partnership with GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S.

    "We believe the future of healthcare is personalized, connected, and truly patient-driven," said Frank Harvey, Chief Executive Officer of Surescripts. "Surescripts has always championed patient choice—whether it's the pharmacy they prefer or the tools they use to manage their care. Our new Script Corner product is a bold step toward that future, empowering patients with price transparency and giving them the freedom to select the pharmacy and savings options that work best for them, including discounted cash prices through our partnership with GoodRx. By meeting patients where they are—digitally, clinically and financially—we're simplifying the medication experience and putting meaningful choices directly in their hands."

    What is Script Corner?

    • Script Corner is a mobile-friendly, web application that will empower patients with the prescription price transparency they need to affordably get and stay on treatment.
    • With Script Corner, when a prescriber at a participating health system transmits an eligible electronic prescription, the patient will receive a secure text message with a personalized web link where they can choose to view prescription details.
    • Script Corner is the only solution that will give patients instant visibility into the cost of their prescription at their chosen pharmacy, including their insurance copay price, GoodRx discounted cash price, as well as other available savings programs, allowing them to choose the most affordable path and helping them avoid costly surprises when they pick up their prescription.
    • All pharmacies are automatically included in Script Corner as part of Surescripts' electronic prescribing—there's no need for pharmacies to signup to be sure their price is listed.
    • Over time, Script Corner will include additional functionality for patients, including medication management, help with onboarding and enrollment in patient support programs and personalized adherence alerts.
    • Script Corner will be available to patients through select health systems in Illinois and Texas in late January then rolled out more broadly throughout 2026.

    "Working with Surescripts allows us to reach patients at a pivotal moment, right after a prescription is written, when they're trying to understand what it will cost," said Wendy Barnes, President and CEO of GoodRx. "By eliminating cost surprises earlier than ever, we help more patients start and stay on therapy and ensure affordability programs reach the patients they're intended to serve."

    Benefits Across the Healthcare Ecosystem

    By integrating Surescripts' market-leading health intelligence network with GoodRx's proven prescription savings, Script Corner creates a more connected, efficient and affordable medication experience for the entire healthcare ecosystem:

    • Patients gain upfront clarity into pricing and savings options, helping them understand the cost of their prescription and choose the option that works best for them, so they can move confidently from prescription to pick up.
    • Health systems are able to give patients greater choice, which could help them avoid delays or the need to switch therapies, leading to reduced prescription abandonment and improved medication adherence.
    • Pharmaceutical companies' affordability programs can reach patients the moment they receive a prescription for a brand medication, helping more patients start and stay on therapy.
    • Pharmacy benefit managers and health plans retain better visibility into their patients' prescriptions and their members quickly see the benefits-based pricing options for their medication so that they can choose the option that works best for them and ensure they adhere to their treatment plan.
    • Pharmacies experience less counter friction and reduced abandonment because patients receive complete pricing information upfront and know what to expect when they arrive at the pharmacy for pick up. When integrated with the GoodRx e-commerce experience, Script Corner provides the added benefit of enabling patients to choose a GoodRx price and pay online before pickup, giving pharmacies full claim and payment details in advance and reducing reprocessing.

    Addressing a National Challenge

    Script Corner is designed to close long-standing gaps between prescribing and pickup that often keep patients from getting the treatments they need. In a recent survey, 87% of prescribers said patients ask to delay or change prescriptions due to out-of-pocket costs very or somewhat often. And 95% of providers believe tools to identify more affordable drug alternatives would be very or somewhat helpful in supporting more satisfying patient interactions.

    GoodRx and Surescripts will discuss Script Corner in further detail at the J.P. Morgan Healthcare Conference on January 13, 2026, at 1:30 p.m. PT.

    About Surescripts

    Our purpose is to serve the nation through simpler, trusted health intelligence sharing, in order to increase patient safety, lower costs and ensure quality care. At Surescripts, we bring healthcare together to inform and accelerate decisions, helping keep patient care on track. With the Surescripts Network Alliance®, we're empowering the healthcare ecosystem with intelligence and interoperability for smarter, faster prescribing, prior authorization, treatment, care management and more. Visit us at surescripts.com and follow us on LinkedIn.

    About GoodRx

    GoodRx is the leading platform for medication savings in the U.S., used by nearly 30 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $85 billion on the cost of their medications.

    ​GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx's website regularly for important information, in addition to following GoodRx's press releases, filings with the Securities and Exchange Commission (the "SEC") and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx's website is not incorporated by reference into, and is not a part of, this press release.

    GoodRx Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated savings, convenience and accessibility; the expected benefits and value of the GoodRx and Surescripts partnership; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260113093588/en/

    Media Contacts

    Kate Giaquinto

    (571) 290-6859

    [email protected]

    and

    [email protected]

    Get the next $GDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    2/27/2026Overweight → Neutral
    Analyst
    1/22/2026$2.75Buy → Hold
    Jefferies
    12/9/2025$3.00Underweight
    Barclays
    8/11/2025Strong Buy → Outperform
    Raymond James
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rey-Giraud Agnes exercised 192,185 shares at a strike of $0.47, gifted 75,219 shares and received a gift of 75,219 shares, increasing direct ownership by 313% to 352,852 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    3/13/26 7:22:26 PM ET
    $GDRX
    EDP Services
    Technology

    Chief Accounting Officer Nabiey Romin converted options into 12,434 shares and covered exercise/tax liability with 5,121 shares, increasing direct ownership by 4% to 183,061 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    3/9/26 5:19:20 PM ET
    $GDRX
    EDP Services
    Technology

    SEC Form 4 filed by Officer Mcginnis Christopher A

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    3/5/26 8:11:56 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GoodRx downgraded by Analyst

    Analyst downgraded GoodRx from Overweight to Neutral

    2/27/26 8:28:37 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx downgraded by Jefferies with a new price target

    Jefferies downgraded GoodRx from Buy to Hold and set a new price target of $2.75

    1/22/26 8:25:34 AM ET
    $GDRX
    EDP Services
    Technology

    Barclays initiated coverage on GoodRx with a new price target

    Barclays initiated coverage of GoodRx with a rating of Underweight and set a new price target of $3.00

    12/9/25 8:49:54 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    SEC Filings

    View All

    GoodRx Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    3/18/26 4:59:09 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    3/6/26 4:38:47 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    2/27/26 4:31:05 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications

    Collaboration expands access to trusted therapies with discounted cash prices for leading brands including Lipitor®, Celebrex®, Viagra®, and Norvasc® GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced a new collaboration with Viatris, a global healthcare company, to make 17 of its established brand medications more affordable for consumers. Beginning today, eligible commercially insured patients may pay as low as $0–$4 on select Viatris medications through GoodRx. Cash-paying consumers, regardless of insurance status, can use GoodRx to access discounted cash prices of up to 85% off at more than 70,000 pharmacies nationwide. The collaboration i

    3/11/26 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx to Expand Employer-Sponsored Access to Zepbound® KwikPen®

    GoodRx Employer Direct enables self-insured employers to subsidize the $449 Lilly Employer Connect medication price for Zepbound KwikPen to reduce employee out-of-pocket costs Brief Summary: GoodRx to collaborate with Eli Lilly to expand employer-sponsored access to Zepbound® KwikPen®, an FDA-approved dual GIP and GLP-1 obesity treatment Through GoodRx Employer Direct, self-insured employers can subsidize Lilly's $449 discounted medication price for Zepbound KwikPen Employer contributions are applied to the medication cost, reducing employee out-of-pocket costs GoodRx integrates manufacturer discounted pricing and employer funding in real time; optional telemedicine supports p

    3/6/26 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Expands Into Employer Market With Launch of "GoodRx Employer Direct"

    New program combines employer-subsidized discounted cash prices and custom telemedicine solutions with existing health benefits to close coverage gaps and support access to high-impact medications GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced the launch of GoodRx Employer Direct. The new offering enables employers to directly lower the cost of high-impact brand medications, including GLP-1s, by applying targeted subsidies to discounted cash prices from pharmaceutical manufacturers. Employers can also deploy branded versions of GoodRx's condition-specific telemedicine solutions, integrating clinical care, prescribing, and pharmacy fulfillm

    2/24/26 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    12/4/23 4:35:10 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/30/23 4:41:35 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/17/23 7:08:30 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Leadership Updates

    Live Leadership Updates

    View All

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity

    Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for

    6/5/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

    Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

    3/17/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Financials

    Live finance-specific insights

    View All

    GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for prescription savings in the U.S., today announced it will release its fourth quarter and full year 2025 financial results after U.S. markets close on Wednesday, February 25, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, February 26, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live

    1/28/26 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports Third Quarter 2025 Results

    Company Maintains Full Year 2025 Revenue and Adjusted EBITDA Expectations; Raises Pharma Manufacturer Solutions Revenue Outlook to Approximately 35% Year-Over-Year Growth for 2025 GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the third quarter of 2025. Third Quarter 2025 Highlights Revenue of $196.0 million Net income of $1.1 million; Net income margin of 0.6% Adjusted Net Income1 of $28.8 million; Adjusted Net Income Margin1 of 14.7% Adjusted EBITDA1 of $66.3 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of

    11/4/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its third quarter 2025 financial results after U.S. markets close on Tuesday, November 4, 2025. GoodRx management will also hold a conference call and webcast the following morning, Wednesday, November 5, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To participate via telephone, please call (800) 715-9871 at least 10 minutes before the conference call is scheduled to begin. The conference ID is 9085550. The call will also be webcast live on the Company's investor relat

    10/8/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/14/24 12:29:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/13/24 4:30:24 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/12/24 4:02:41 PM ET
    $GDRX
    EDP Services
    Technology